Skip to main content
OpenTrials
Completed

NCT Number: NCT01912781

Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers

The purpose of this study is demonstrate substantial equivalence of an investigational contact lens disinfecting solution to a commercially available contact lens solution in gas permeable lens wearers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myopia Astigmatism Eye Diseases Hyperopia Refractive Error Refractive Errors

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Subjects with normal eyes (other than correction for refractive error) successfully wearing silicone acrylate or fluoro silicone acrylate gas permeable contact lenses were randomized 2:1 to receive either the investigational or commercial contact lens solution for daily use throughout the study (90 days).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Normal eyes (other than correction for visual acuity);
  • Successful history of gas permeable contact lens wear in both eyes in one of two brands: Boston XO or Boston II;
  • Best spectacle corrected distance visual acuity greater than or equal to 20/25 in each eye;
  • Other protocol-defined inclusion criteria may apply.

Exclusion criteria

  • Any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the investigational products or affect the results of this study;
  • Need to wear contact lenses on an extended wear basis (ie, overnight) during the study;
  • Use of a daily cleaner and/or an enzyme cleaner to care for lenses at least 7 days prior to Visit 1;
  • History of intolerance or hypersensitivity to any component of the investigational products;
  • Use of all over-the-counter (OTC) or prescribed topical ocular medications within 7 days prior to Visit 1;
  • Moderate, severe, abnormal, or other ocular findings;
  • Current or history of ocular infection, severe inflammation, or disease within 6 months prior to Visit 1;
  • Any systemic disease at Visit 1 (including allergies, respiratory infections or colds) that may affect the eye or be exacerbated by use of contact lenses or contact lens solutions;
  • Use of systemic medications that may contribute to adverse ocular effects unless on a stable dosing regimen;
  • Ocular surgery within the last 12 months;
  • Other protocol-defined exclusion criteria may apply.

Treatment and study plan

FID 120947A contact lens disinfecting solution

Device

Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses

Other names: Clear Care® Plus

Boston Simplus multi-action solution

Device

Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses

Gas permeable contact lenses

Device

Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).

Other names: Boston XO, Boston II

Primary outcomes

  1. Percentage of Subjects With Visibly Clean Lenses

    Time frame: Day 7, Day 30, Day 60, Day 90

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered. A lens was considered visibly clean if it had nondetectable films or deposits. One eye (study eye) contributed to the analysis.

  2. Percentage of Subjects With Crystalline Deposits by Type

    Time frame: Day 7, Day 30, Day 60, Day 90

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered: Type II = films or deposits visible only under special conditions, such as special illumination using an eyepiece of 7-10 times magnification, Type III = films or deposits readily visible on a dry lens under room lighting, with unaided eye, and Type IV = films or deposits obvious under room lighting, with unaided eye, when the lens is wet or dry. One eye (study eye) contributed to the analysis.

  3. Percentage of Subjects With Film Deposits by Type

    Time frame: Day 7, Day 30, Day 60, Day 90

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered: Type II = films or deposits visible only under special conditions, such as special illumination using an eyepiece of 7-10 times magnification, Type III = films or deposits readily visible on a dry lens under room lighting, with unaided eye, and Type IV = films or deposits obvious under room lighting, with unaided eye, when the lens is wet or dry. One eye (study eye) contributed to the analysis.

  4. Average Residual Lens Lysozyme

    Time frame: Day 90/Early Exit

    Worn study lenses were removed and analyzed by high performance liquid chromatography (HPLC) for residual lens lysozyme (protein). Values reported as lower than the limit of quantitation or none detected were imputed as 0.5 μg or 0 μg, respectively. A lower value indicates less lysozyme deposition. One eye (study eye) contributed to the analysis.

  5. Percentage of Subjects With Change From Baseline in Contact Lens-Corrected Distance Visual Acuity (CLCDVA) by Line Change

    Time frame: Baseline (Day 0), Day 7, Day 30, Day 60, Day 90

    Distance VA was assessed for each eye individually while reading a chart distant to the participant in dimmed room illumination. VA was measured using a Snellen chart, with 20/20 Snellen acuity considered normal distance-eyesight. A line increase indicates an improvement in VA. One eye (study eye) contributed to the analysis.

  6. Average Lens Wear Time

    Time frame: Day 7, Day 30, Day 60, Day 90

    Subject recorded a response to the question, "Averaging over the last 3 days, how many hours per day did you wear your contact lenses?" Lens wear time was measured in hours.

  7. Number of Unscheduled Lens Replacements by Reason

    Time frame: Up to Day 90

    No lens replacements were planned during the study. Lenses could be replaced as needed due to loss, damage, or as deemed necessary by the Investigator. If it became necessary to replace a lens, the subject was examined at an unscheduled visit. The counts in the table represent the total number of unscheduled lenses replaced by reason for any eye, any subject.

  8. Likert Item - "When I Use This Solution, my Lenses Are Comfortable All Day."

    Time frame: Day 7, Day 30, Day 60, Day 90

    Lens comfort was assessed by the subject as a single response on a 5-point Likert scale (Strongly Agree, Agree, Undecided, Disagree, Strongly Disagree) to best describe their lens wearing experience over the last 3 days. Responses were summarized by agreement category and presented as percentage of subjects.

  9. Likert Item - "When I Use This Solution, at the End of the Lens Wearing Day my Vision is Clear."

    Time frame: Day 7, Day 30, Day 60, Day 90

    Clear vision was assessed by the subject as a single response on a 5-point Likert scale (Strongly Agree, Agree, Undecided, Disagree, Strongly Disagree) to best describe their lens wearing experience over the last 3 days. Responses were summarized by agreement category and presented as percentage of subjects.

  10. Likert Item - "When I Use This Solution, I Like the Way This Product Feels During Handling."

    Time frame: Day 7, Day 30, Day 60, Day 90

    Product handling was assessed by the subject as a single response on a 5-point Likert scale (Strongly Agree, Agree, Undecided, Disagree, Strongly Disagree) to best describe their lens wearing experience over the last 3 days. Responses were summarized by agreement category and presented as percentage of subjects.

  11. Crystalline Deposit Area Covered

    Time frame: Day 7, Day 30, Day 60, Day 90

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered. Values were reported as a percentage of lens area covered. One eye (study eye) contributed to the analysis.

  12. Film Deposit Area Covered

    Time frame: Day 7, Day 30, Day 60, Day 90

    Worn study lenses were removed and evaluated for deposits. Deposits found on the lenses were defined using a 3-part classification system consisting of general visibility, the specific appearance and area covered. Values were reported as a percentage of lens area covered. One eye (study eye) contributed to the analysis.

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Official study title

Clinical Evaluation of the Safety and Efficacy of FID 120947A Compared to a Marketed Lens Care Solution in Gas Permeable Contact Lens Wearers

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jul 31, 2013
Registry last updated
Jun 30, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.